疏血通联合西医常规治疗脑梗塞急性期随机平行对照研究

Shuxuetong Joint Controlled Study Randomized Parallel Conventional Western Medicine with Cerebral Infarction

[目的]观察疏血通联合西医常规治疗脑梗塞急性期疗效。[方法]使用随机平行对照方法,将90例门诊及住院患者按就诊顺序编号法简单随机分为两组。对照组46例西医常规治疗,低分子肝素,阿司匹林,最低有效剂量为50mg或75mg/d,急性期可增加剂量至300mg/d。治疗组44例疏血通6m L＋5%葡萄糖250-500m L静滴,1次/d;西医常规治疗同对照组。连续治疗2周为1疗程。观测临床症状、神经功能缺损评分（NIHSS）量表、Barthel生活能力评分量表、不良反应。治疗1疗程,判定疗效。[结果]治疗组显效21例,有效12例,无效11例,总有效率75.00%。对照组显效15例,有效15例,无效16例,总有效率65.22%。治疗组疗效优于对照组（P〈0.05,P〈0.01）。神经功能缺损评分及Barthel生活能力评分两组均有改善（P〈0.05）,治疗组改善优于对照组（P〈0.05）。[结论]疏血通联合西医常规治疗脑梗塞急性期,疗效满意,无严重不良反应,值得推广。

[Objective]To observe Shuxuetong conventional western medicine combined with acute cerebral infarction treatment.[Method]Randomized,parallel controlled method,90 cases of outpatient and inpatient treatment order number method is simple and randomly divided into two groups.The control group of 46 patients conventional western medicine,intravenous thrombolysis administered heparin,low molecular weight heparin implementation anticoagulation,aspirin antiplatelet,the lowest effective dose of 50 mg or 75mg/d,the acute phase can increase the dose to 300mg/d.The treatment group 44 cases Shuxuetong 6m L＋5% glucose 250-500m L infusion,1/d;conventional western medicine with the control group.Continuous treatment for two weeks for a course.Observation of clinical symptoms,neurological deficits（NIHSS）Scale,Barthel living rating scale,adverse reactions.One course of treatment,to determine efficacy.[Results]The treatment group 21 cases,12 cases,11 cases,the total efficiency of 75.00%.The control group 15 cases markedly effective in 15 cases,16 cases,the total efficiency of 65.22%.Treatment group than the control group（P〈0.05,P〈0.01）.Neurological deficit score and Barthel score viability in both groups improved（P〈0.05）,treatment group was better than that in the control group（P〈0.05）.[Conclusion]Shuxuetong conventional Western medicine combined with acute cerebral infarction,results were satisfactory,no serious adverse reactions,should be promoted.（1.Guangzhou University of Chinese Medicine Affiliated Hospital Oncology,Foshan 528333,Guangdong, China;2.College of traditional Chinese Medicine Internal Medicine Teaching and Research Section of Chinese Medicine,Southern Medical University,Guangzhou 510515,China）（1.Guangzhou University of Chinese Medicine Affiliated Hospital Oncology,Foshan 528333,Guangdong, China;2.College of traditional Chinese Medicine Internal Medicine Teaching and Research Section of Chinese Medicine,Southern Medical University,Guangzhou 510515,China）